Innovation & Research

Our Pipeline and Products

Menarini is investing in advanced science and technology to develop a pipeline of new products that make a difference to the lives of patients affected by serious conditions.

Our pipeline refers to drugs in development, including those in preclinical testing, clinical development, regulatory approval and lifecycle management.

The information in the table reflects Menarini's development pipeline and is not intended for promotional or marketing purposes. The safety and efficacy of the investigational compounds, or investigational uses of marketed products have not been established and marketing approval has yet to be granted by regulatory authorities.

Oncology

Compound
Mechanism Of Action
Indication
Development Stage
Tagraxofusp
Stemline Therapeutics
Targeted Biologic (CD123)
Blastic plasmacytoid dendritic cell neoplasm
P
Ia
Ib
II
III
F
A
Read More

Targeted Biologic (CD123)
Blastic plasmacytoid dendritic cell neoplasm
P
Ia
Ib
II
III
F
A
Read More

Targeted Biologic (CD123)
Chronic myelomonocytic leukemia
P
Ia
Ib
II
III
F
A
Read More

Targeted Biologic (CD123)
Myelofibrosis
P
Ia
Ib
II
III
F
A
Read More
Elacestrant
Radius Health
SERD (ER)
Breast cancer
P
Ia
Ib
II
III
F
A
Read More
SL-701
Immunotherapy (IL-13Rα2, EphA2, Survivin)
Glioblastoma multiforme
P
Ia
Ib
II
III
F
A
Read More
MEN1703
Ryvu Therapeutics
SME (PIM/FLT3i)
Acute myeloid leukemia
P
Ia
Ib
II
III
F
A
Read More
MEN1611
Chugai
SME (PI3Ki)
Breast cancer
P
Ia
Ib
II
III
F
A
Read More

SME (PI3Ki)
Colorectal cancer
P
Ia
Ib
II
III
F
A
Read More
MEN1112
Oxford Bio Therapeutics
mAB (Anti-CD157)
Acute myeloid leukemia
P
Ia
Ib
II
III
F
A
Read More
MEN1309
Oxford Bio Therapeutics
ADC (Anti-CD205)
Solid tumors
P
Ia
Ib
II
III
F
A
Read More
Felezonexor
Stemline Therapeutics
SME (XP01i)
Solid tumors
P
Ia
Ib
II
III
F
A
Read More
SL-901
Stemline Therapeutics
SME (PI3Ki)
Solid tumors
P
Ia
Ib
II
III
F
A
Read More
SL-1001
Stemline Therapeutics
SME (RETi)
Solid tumors
P
Ia
Ib
II
III
F
A
Read More
Legenda
ABSSSI: Acute Bacterial Skin and Skin Structure Infections
ADC: Antibody Drug Conjugate   
CABP: Community Acquired Bacterial Pneumonia
cIAI: complicated Intra-Abdominal Infections
cUTI: complicated Urinary Tract Infections
ER: Estrogen receptor
HABP: Hospital Acquired Bacterial Pneumonia
IV: Intravenous
mAb: monoclonal antibody  
PIM/FLT3i: PIM/FLT3 kinase inhibitor
PI3Ki: phosphatidylinositol 3-kinase inhibitor
RETi: RET kinase inhibitor
SME: Small Molecule Entity
VABP: Ventilator Associated Bacterial Pneumonia
XPO1i: XPO1 Inhibitor


P: Preclinical
I: Phase I
II: Phase II
III: Phase III
F: Filing
A: Approval


Anti-infectives

Compound
Mechanism Of Action
Indication
Development Stage
Meropenem + Vaborbactam
Melinta Therapeutics
Carbapenem + β-lactamase inhibitor
cUTI, cIAI, HABP, VABP and Bacteremia
P
Ia
Ib
II
III
F
A
Read More

Carbapenem + β-lactamase inhibitor
cUTI, cIAI, HABP, VABP and Bacteremia
P
Ia
Ib
II
III
F
A
Read More
Delafloxacin
Melinta Therapeutics
Anionic fluoroquinolone
ABSSSI
P
Ia
Ib
II
III
F
A
Read More

Anionic fluoroquinolone
CABP
P
Ia
Ib
II
III
F
A
Read More
Oritavancin
Melinta Therapeutics
Semisynthetic glycopeptide
ABSSSI
P
Ia
Ib
II
III
F
A
Read More

Semisynthetic glycopeptide
ABSSSI
P
Ia
Ib
II
III
F
A
Read More
Legenda
ABSSSI: Acute Bacterial Skin and Skin Structure Infections
ADC: Antibody Drug Conjugate
CABP: Community Acquired Bacterial Pneumonia
cIAI: complicated Intra-Abdominal Infections
cUTI: complicated Urinary Tract Infections
ER: Estrogen receptor
HABP: Hospital Acquired Bacterial Pneumonia
IV: Intravenous
mAb: monoclonal antibody
PIM/FLT3i: PIM/FLT3 kinase inhibitor
PI3Ki: phosphatidylinositol 3-kinase inhibitor
RETi: RET kinase inhibitor
SME: Small Molecule Entity
VABP: Ventilator Associated Bacterial Pneumonia
XPO1i: XPO1 Inhibitor


P: Preclinical
I: Phase I
II: Phase II
III: Phase III
F: Filing
A: Approval

Search Menarini in the world

v

Etiam commodo dui eget wisi. Donec iaculis gravida nulla. Donec quis nibh at felis congue commodo. Etiam bibendum elit eget erat.

Partnering

Drug development is a challenging process, and success relies on the integration of innovative scientific discoveries with the necessary capabilities and resources to transform them into effective healthcare solutions.

Read More